Edition:
India

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

119.45USD
11 Oct 2019
Change (% chg)

$2.90 (+2.49%)
Prev Close
$116.55
Open
$117.75
Day's High
$120.46
Day's Low
$117.53
Volume
71,314
Avg. Vol
96,969
52-wk High
$164.64
52-wk Low
$105.19

Latest Key Developments (Source: Significant Developments)

Beigene Posts HY Net Loss Attributable Of US$253.2 Million
Thursday, 29 Aug 2019 

Aug 29 (Reuters) - Beigene Ltd <6160.HK>::HY TOTAL REVENUES INCREASED BY 276.3% TO US$321.2 MILLION.HY NET LOSS ATTRIBUTABLE $253.2 MILLION VERSUS LOSS OF $261.5 MILLION.  Full Article

BeiGene Announces U.S. FDA Acceptance And Grant Of Priority Review For Its New Drug Application Of Zanubrutinib
Thursday, 22 Aug 2019 

Aug 21 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE ANNOUNCES U.S. FDA ACCEPTANCE AND GRANT OF PRIORITY REVIEW FOR ITS NEW DRUG APPLICATION OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA.BEIGENE LTD - FDA GRANTED PRIORITY REVIEW FOR NDA AND HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF FEBRUARY 27, 2020.  Full Article

Beigene Granted Approval To Transition From The Biotech Chapter Of The Hong Kong Stock Exchange To A General Listing
Friday, 28 Jun 2019 

June 28 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE GRANTED APPROVAL TO TRANSITION FROM THE BIOTECH CHAPTER OF THE HONG KONG STOCK EXCHANGE TO A GENERAL LISTING.BEIGENE LTD - "B" MARKER WILL BE REMOVED FROM COMPANY'S STOCK SYMBOL IN HKEX.BEIGENE LTD - COMPANY'S ORDINARY SHARES MAY BECOME ELIGIBLE FOR LISTING IN HANG SENG INDICES..  Full Article

BeiGene Presents Phase 2 Results Of Zanubrutinib In Patients With Leukemia Or Lymphoma
Thursday, 20 Jun 2019 

June 20 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE PRESENTS PIVOTAL PHASE 2 CLINICAL RESULTS OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA AT THE 15TH INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA (ICML).BEIGENE LTD - ZANUBRUTINIB TOLERABILITY WAS GENERALLY CONSISTENT WITH PREVIOUS REPORTS.BEIGENE LTD - THREE PATIENTS HAD TEAES LEADING TO DEATH; THESE WERE DETERMINED UNLIKELY OR UNRELATED TO ZANUBRUTINIB TREATMENT.BEIGENE LTD - ORR BY IRC WAS 84.6%; COMPLETE RESPONSE (CR) RATE WAS 3.3%.BEIGENE LTD - AS OF DEC 14, 2018 DATA CUTOFF, 75 PATIENTS (82.4%) REMAINED ON STUDY TREATMENT.  Full Article

Beigene Announces Acceptance Of Supplemental Import Drug Application In China For Abraxane
Friday, 31 May 2019 

May 30 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE ANNOUNCES ACCEPTANCE OF SUPPLEMENTAL IMPORT DRUG APPLICATION IN CHINA FOR ABRAXANE® IN METASTATIC PANCREATIC CANCER.BEIGENE LTD- CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION HAS ACCEPTED SUPPLEMENTAL IMPORT DRUG APPLICATION FOR ABRAXANE.  Full Article

Beigene Posts Qtrly Net Loss Attributable Of $167.6 Million
Friday, 10 May 2019 

May 10 (Reuters) - Beigene Ltd <6160.HK>::QTRLY NET LOSS ATTRIBUTABLE TO BEIGENE, LTD. $167.6 MILLION VERSUS LOSS OF $104.6 MILLION.QTRLY TOTAL REVENUES $77.8 MILLION VERSUS $32.5 MILLION.  Full Article

BeiGene Q1 Loss Per Share $0.22
Friday, 10 May 2019 

May 9 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.22.COLLABORATION REVENUE TOTALED $20.41 MILLION FOR Q1 ENDED MARCH 31, 2019, COMPARED TO $9.29 MILLION FOR SAME PERIOD IN 2018.QTRLY LOSS PER SHARE $0.22.  Full Article

Beigene Ltd Says CEO's Total Compensation For FY 2018 Was $27.9 Mln Versus $10.3 Mln In FY 2017
Monday, 29 Apr 2019 

April 29 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE LTD SAYS CEO JOHN V. OYLER'S TOTAL COMPENSATION FOR FY 2018 WAS $27.9 MILLION VERSUS $10.3 MILLION IN FY 2017- SEC FILING.BEIGENE LTD SAYS GENERAL MANAGER OF CHINA AND PRESIDENT XIAOBIN WU'S TOTAL COMPENSATION FOR FY 2018 WAS $21.5 MILLION.BEIGENE LTD - RATIO OF 2018 ANNUAL TOTAL COMPENSATION OF CEO TO MEDIAN OF ANNUAL TOTAL COMPENSATION OF ALL EMPLOYEES IS 135:1.  Full Article

Bioatla And Beigene Form Worldwide Collaboration To Develop And Commercialize Novel Conditionally Active Biologic Ctla-4 Therapy
Tuesday, 9 Apr 2019 

April 9 (Reuters) - Beigene Ltd <6160.HK>::BIOATLA AND BEIGENE FORM WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE NOVEL CONDITIONALLY ACTIVE BIOLOGIC CTLA-4 THERAPY.BIOATLA LLC - WILL RECEIVE AN UPFRONT PAYMENT OF $20 MILLION AND A MILESTONE PAYMENT UPON REACHING DEFINED EARLY CLINICAL OBJECTIVES.BIOATLA - BEIGENE WILL HOLD A CO-EXCLUSIVE LICENSE WITH BIOATLA TO DEVELOP AND MANUFACTURE PRODUCT CANDIDATE GLOBALLY.BIOATLA - IS ALSO ELIGIBLE TO RECEIVE UP TO $249 MILLION IN MILESTONE PAYMENTS.  Full Article

Beigene Reports Qtrly Loss Per Share Of $0.35
Thursday, 28 Feb 2019 

Feb 27 (Reuters) - Beigene Ltd <6160.HK>::BEIGENE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.BEIGENE LTD QTRLY NET LOSS PER ADS ATTRIBUTABLE TO BEIGENE LTD $4.52.BEIGENE LTD QTRLY LOSS PER SHARE $0.35.BEIGENE LTD QTRLY TOTAL REVENUES $58.67 MILLION VERSUS $18.17 MILLION.  Full Article